AAAAAA
Results:
1-18
|
Results: 18
Authors:
Mazurier, C
Goudemand, J
Hilbert, L
Caron, C
Fressinaud, E
Meyer, D
Citation: C. Mazurier et al., Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology, BEST P R C, 14(2), 2001, pp. 337-347
Authors:
Meyer, D
Fressinaud, E
Hilbert, L
Ribba, AS
Lavergne, JM
Mazurier, C
Citation: D. Meyer et al., Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function, BEST P R C, 14(2), 2001, pp. 349-364
Authors:
Poon, MC
d'Oiron, R
Hann, I
Negrier, C
de Lumley, L
Thomas, A
Karafoulidou, A
Demers, C
Street, A
Huth-Kuhne, A
Petrini, P
Fressinaud, E
Morfini, M
Tengborn, L
Marques-Verdier, A
Musso, R
Devecioglu, O
Houston, DS
Lethagen, S
Van Geet, C
von Depka, M
Berger, C
Beurrier, P
Britton, HA
Gerrits, W
Guthner, C
Kuhle, S
Lorenzo, JJ
Makris, PE
Nohe, N
Paugy, P
Pautard, B
Torchet, MF
Trillot, N
Vicariot, M
Wilde, J
Winter, M
Chambost, H
Ingerslev, J
Peters, M
Strauss, G
Citation: Mc. Poon et al., Use of recombinant factor VIIa (NovoSeven (R)) in patients with Glanzmann thrombasthenia, SEM HEMATOL, 38(4), 2001, pp. 21-25
Authors:
Ruiz, C
Liu, CY
Sun, QH
Sigaud-Fiks, M
Fressinaud, E
Muller, JY
Nurden, P
Nurden, AT
Newman, PJ
Valentin, N
Citation: C. Ruiz et al., A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alpha IIb beta 3) integrin receptorlocked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype, BLOOD, 98(8), 2001, pp. 2432-2441
Authors:
Ribba, AS
Hilbert, L
Lavergne, JM
Fressinaud, E
Boyer-Neumann, C
Ternisien, C
Juhan-Vague, I
Goudemand, J
Girma, JP
Mazurier, C
Meyer, D
Citation: As. Ribba et al., The arginine-552-cysteine (R1315C) mutation within the Al loop of von Willebrand factor induces an abnormal folding with a loss of function resultingin type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor, BLOOD, 97(4), 2001, pp. 952-959
Authors:
Veyradier, A
Fressinaud, E
Boyer-Neumann, C
Trossaert, M
Meyer, D
Citation: A. Veyradier et al., von Willebrand factor ristocetin cofactor activity correlates with platelet function in a high shear stress system, THROMB HAEM, 84(4), 2000, pp. 727-728
Authors:
Veyradier, A
Jenkins, CSP
Fressinaud, E
Meyer, D
Citation: A. Veyradier et al., Acquired von Willebrand syndrome: from pathophysiology to management, THROMB HAEM, 84(2), 2000, pp. 175-182
Authors:
d'Oiron, R
Menart, C
Trzeciak, MC
Nurden, P
Fressinaud, E
Dreyfus, M
Laurian, Y
Negrier, C
Citation: R. D'Oiron et al., Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing inversive procedures, THROMB HAEM, 83(5), 2000, pp. 644-647
Authors:
Tout, H
Obert, B
Houllier, A
Fressinaud, E
Rothschild, C
Meyer, D
Girma, JP
Citation: H. Tout et al., Mapping and functional studies of two alloantibodies developed in patientswith type 3 von Willebrand disease, THROMB HAEM, 83(2), 2000, pp. 274-281
Authors:
Costa, JM
Vidaud, D
Laurendeau, I
Vidaud, M
Fressinaud, E
Moisan, JP
David, A
Meyer, D
Lavergne, JM
Citation: Jm. Costa et al., Somatic mosaicism and compound heterozygosity in female hemophilia B, BLOOD, 96(4), 2000, pp. 1585-1587
Authors:
Jorieux, S
Fressinaud, E
Goudemand, J
Gaucher, C
Meyer, D
Mazurier, C
Citation: S. Jorieux et al., Conformational changes in the D ' domain of von Willebrand factor induced by CYS 25 and CYS 95 mutations lead to factor VIII binding defect and multimeric impairment, BLOOD, 95(10), 2000, pp. 3139-3145
Authors:
Zini, JM
Durocher, A
Blettery, B
Fonlupt, J
Hofliger, P
Laurian, Y
Mangola, B
Roubertie, E
Sultan, Y
Vicariot, M
Delobel, J
Derlon, A
Ducluzeau, R
Fressinaud, E
Gaillard, S
Guerin, V
Guerois, C
Klotz, P
Lauroua, P
Lorenzini, JL
Murat, I
Oberling, F
Perrimond, H
Pierre-Louis, S
Pouzol, P
Richard, D
Rotschild, C
Simon, N
Subtil, E
Tron, P
Brucker, P
Cordier, H
Dindaine, ML
Citation: Jm. Zini et al., Emergency management of hemophiliacs with suspected hemorrhage, PRESSE MED, 28(11), 1999, pp. 591-595
Authors:
Obert, B
Tout, H
Veyradier, A
Fressinaud, E
Meyer, D
Girma, JP
Citation: B. Obert et al., Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF, THROMB HAEM, 82(5), 1999, pp. 1382-1385
Authors:
Veyradier, A
Fressinaud, E
Sigaud, M
Wolf, M
Meyer, D
Citation: A. Veyradier et al., A new automated method for von Willebrand factor antigen measurement usinglatex particles, THROMB HAEM, 81(2), 1999, pp. 320-321
Authors:
Janel, N
Leroy, C
Laude, I
Toti, F
Fressinaud, E
Meyer, D
Freyssinet, JM
Kerbiriou-Nabias, D
Citation: N. Janel et al., Assessment of the expression of candidate human plasma membrane phospholipid scramblase in Scott syndrome cells, THROMB HAEM, 81(2), 1999, pp. 322-323
Authors:
Fressinaud, E
Veyradier, A
Sigaud, M
Boyer-Neumann, C
Le Boterff, C
Meyer, D
Citation: E. Fressinaud et al., Therapeutic monitoring of von Willebrand disease: interest and limits of aplatelet function analyser at high shear rates, BR J HAEM, 106(3), 1999, pp. 777-783
Authors:
Martinez, MC
Martin, S
Toti, F
Fressinaud, E
Dachary-Prigent, J
Meyer, D
Freyssinet, JM
Citation: Mc. Martinez et al., Significance of capacitative Ca2+ entry in the regulation of phosphatidylserine expression at the surface of stimulated cells, BIOCHEM, 38(31), 1999, pp. 10092-10098
Authors:
Veyradier, A
Fressinaud, E
Meyer, D
Citation: A. Veyradier et al., Laboratory diagnosis of von Willebrand disease, INT J CL L, 28(4), 1998, pp. 201-210
Risultati:
1-18
|